T1	PROC 46 106	Evaluación de la Seguridad, Farmacocinética y Farmacodinamia
T2	DISO 138 161	Enfermedad de Parkinson
#1	AnnotatorNotes T2	C0030567; Parkinson Disease; Disease or Syndrome
T3	PROC 184 257	Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo
T4	CHEM 949 952	DaT
T5	PROC 277 288	tratamiento
#2	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 309 320	enmascarada
#3	AnnotatorNotes T6	C0150108; Blinded; Research Activity
T7	PROC 327 387	evaluar la seguridad, la farmacocinética y la farmacodinamia
T8	DISO 414 437	enfermedad de Parkinson
#4	AnnotatorNotes T8	C0030567; Parkinson Disease; Disease or Syndrome
T9	DISO 462 485	Enfermedad de Parkinson
#5	AnnotatorNotes T9	C0030567; Parkinson Disease; Disease or Syndrome
T10	PROC 514 527	diagnosticado
#6	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	DISO 532 555	Enfermedad de Parkinson
#7	AnnotatorNotes T11	C0030567; Parkinson Disease; Disease or Syndrome
T12	DISO 557 559	EP
#8	AnnotatorNotes T12	C0030567; Parkinson Disease; Disease or Syndrome
T13	CHEM 729 737	levodopa
#9	AnnotatorNotes T13	C0023570; levodopa; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T14	PROC 752 763	tratamiento
#10	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	DISO 772 774	EP
#11	AnnotatorNotes T15	C0030567; Parkinson Disease; Disease or Syndrome
T16	PROC 849 869	pauta de tratamiento
T17	CHEM 110 117	BIIB054
T18	DISO 887 889	EP
#12	AnnotatorNotes T18	C0030567; Parkinson Disease; Disease or Syndrome
T19	PROC 936 952	detección de DaT
T20	PROC 953 958	SPECT
#13	AnnotatorNotes T20	C0040399; Tomography, Emission-Computed, Single-Photon; Diagnostic Procedure
T21	DISO 1030 1061	parkinsonismo neurodegenerativo
T22	DISO 1103 1125	congelamiento al andar
#14	AnnotatorNotes T22	C0860515; Freezing of gait; Finding
T23	DISO 1156 1177	deterioros cognitivos
#15	AnnotatorNotes T23	C0338656; Impaired cognition; Mental or Behavioral Dysfunction | C0854193; Cognitive deterioration; Mental or Behavioral Dysfunction
T24	DISO 1194 1202	demencia
#16	AnnotatorNotes T24	C0497327; Dementia; Mental or Behavioral Dysfunction
T25	CHEM 391 398	BIIB054
T26	CHEM 1526 1533	BIIB054
T27	PROC 1335 1355	resonancia magnética
#17	AnnotatorNotes T27	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T28	PROC 1357 1360	MRI
#18	AnnotatorNotes T28	C0024485; Magnetic Resonance Imaging; Diagnostic Procedure
T29	PROC 664 697	Escala de Hoehn y Yahr modificada
#19	AnnotatorNotes T29	C4274795; Assessment using Modified Hoehn and Yahr Scale; Diagnostic Procedure
T30	DISO 1447 1455	alergias
#20	AnnotatorNotes T30	C1527304; Allergic Reaction; Pathologic Function
T31	DISO 1466 1490	reacciones anafilácticas
#21	AnnotatorNotes T31	C0002792; anaphylaxis; Disease or Syndrome
T32	DISO 1506 1523	hipersensibilidad
#22	AnnotatorNotes T32	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T33	CHEM 1541 1561	ingrediente inactivo
#23	AnnotatorNotes T33	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T34	CHEM 1568 1592	fármaco en investigación
#24	AnnotatorNotes T34	C0013230; Investigational New Drugs; Pharmacologic Substance
T35	CHEM 1597 1610	radioligandos
#25	AnnotatorNotes T35	C0599278; radioligand; Indicator, Reagent, or Diagnostic Aid
T36	CHEM 1613 1617	yodo
#26	AnnotatorNotes T36	C0021968; iodine; Biologically Active Substance · Element, Ion, or Isotope · Pharmacologic Substance
T37	PROC 1139 1143	MOCA
#27	AnnotatorNotes T37	C4555213; Assessment using Montreal cognitive assessment; Diagnostic Procedure
T38	DISO 1372 1385	anormalidades
#28	AnnotatorNotes T38	C1704258; Abnormality; Finding
T39	Date 13 17	2016
T40	PHYS 74 89	Farmacocinética
#29	AnnotatorNotes T40	C0031327; Drug Kinetics; Physiologic Function
T41	PHYS 352 367	farmacocinética
#30	AnnotatorNotes T41	C0031327; Drug Kinetics; Physiologic Function
T42	LIVB 402 409	sujetos
#31	AnnotatorNotes T42	C0681850; Study Subject; Group
T43	Duration 594 613	un máximo de 3 años
T44	LIVB 704 711	sujetos
#32	AnnotatorNotes T44	C0681850; Study Subject; Group
T45	Neg_cue 712 714	no
T46	Neg_cue 740 746	ningún
T47	Duration 783 797	las 12 semanas
T48	Date 809 814	día 1
T49	Neg_cue 890 892	no
T50	Duration 898 917	exceder los 30 días
T52	LIVB 1231 1243	investigador
#33	AnnotatorNotes T52	C0035173; Research Personnel; Professional or Occupational Group
T53	LIVB 1414 1423	radiólogo
#34	AnnotatorNotes T53	C0260194; radiologist; Professional or Occupational Group
T54	PHYS 1167 1177	cognitivos
#35	AnnotatorNotes T54	C0009240; Cognition; Mental Process
T55	PHYS 92 106	Farmacodinamia
#36	AnnotatorNotes T55	C0851347; Pharmacodynamics; Biologic Function
T56	PHYS 373 387	farmacodinamia
#37	AnnotatorNotes T56	C0851347; Pharmacodynamics; Biologic Function
T57	PHYS 1120 1125	andar
#38	AnnotatorNotes T57	C0945826; Ambulation; Organism Function
T51	LIVB 121 133	participante
#39	AnnotatorNotes T51	C4554048; Study Participant; Population Group
T58	PROC 965 984	visita de selección
#40	AnnotatorNotes T58	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T59	PROC 1310 1316	visita
#41	AnnotatorNotes T59	C1512346; Patient Visit; Health Care Activity
T60	Quantifier_or_Qualifier 1317 1326	de inicio
A1	Assertion T13 Negated
A2	Assertion T14 Negated
A3	Assertion T50 Negated
A4	Status T38 History_of
A5	Status T30 History_of
A6	Status T31 History_of
A7	Status T32 History_of
#43	AnnotatorNotes T17	C5418330; Cinpanemab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#44	AnnotatorNotes T25	C5418330; Cinpanemab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#45	AnnotatorNotes T26	C5418330; Cinpanemab; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Immunologic Factor 
#46	AnnotatorNotes T3	C1096776; Multicenter Study; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
T61	Spec_cue 1244 1250	podría
T62	CONC 1251 1261	interferir
A8	Assertion T62 Speculated
#42	AnnotatorNotes T62	C0521102; Interferes with; Functional Concept
R1	Speculation Arg1:T61 Arg2:T62	
R2	Experiences Arg1:T51 Arg2:T17	
R3	Experiences Arg1:T51 Arg2:T2	
T63	Quantifier_or_Qualifier 289 295	activo
#47	AnnotatorNotes T63	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R4	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T63	
R5	Overlap Arg1:T5 Arg2:T6	
R6	Experiences Arg1:T51 Arg2:T40	
R7	Experiences Arg1:T51 Arg2:T55	
R8	Experiences Arg1:T42 Arg2:T41	
R9	Experiences Arg1:T42 Arg2:T56	
R10	Experiences Arg1:T42 Arg2:T25	
R11	Experiences Arg1:T42 Arg2:T8	
R12	Experiences Arg1:T42 Arg2:T5	
R13	Used_for Arg1:T25 Arg2:T5	
T64	CONC 303 308	dosis
#48	AnnotatorNotes T64	C0178602; Dosage; Quantitative Concept
R14	Has_Quantifier_or_Qualifier Arg1:T64 Arg2:T6	
R15	Has_Duration_or_Interval Arg1:T12 Arg2:T43	
R16	Has_Duration_or_Interval Arg1:T11 Arg2:T43	
T65	Quantifier_or_Qualifier 561 585	establecida clínicamente
R17	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T65	
R18	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T65	
T66	PROC 626 635	selección
#49	AnnotatorNotes T66	C0242802; Patient Selection; Research Activity
R19	Before Arg1:T11 Arg2:T66	
R20	Before Arg1:T12 Arg2:T66	
T67	Result_or_Value 653 657	≤2,5
R21	Has_Result_or_Value Arg1:T29 Arg2:T67	
R22	Experiences Arg1:T44 Arg2:T13	
R23	Experiences Arg1:T44 Arg2:T14	
R24	Negation Arg1:T46 Arg2:T14	
R25	Negation Arg1:T45 Arg2:T13	
R26	Experiences Arg1:T44 Arg2:T15	
R27	Has_Duration_or_Interval Arg1:T13 Arg2:T47	
R28	Has_Duration_or_Interval Arg1:T14 Arg2:T47	
R29	Before Arg1:T14 Arg2:T48	
R30	Before Arg1:T13 Arg2:T48	
R31	Before Arg1:T16 Arg2:T48	
R32	Has_Duration_or_Interval Arg1:T16 Arg2:T50	
R33	Negation Arg1:T49 Arg2:T50	
R34	Experiences Arg1:T44 Arg2:T18	
R35	Experiences Arg1:T44 Arg2:T16	
R36	Overlap Arg1:T20 Arg2:T58	
R37	Overlap Arg1:T19 Arg2:T58	
#50	AnnotatorNotes T4	C0114838; dopamine transporter; Amino Acid, Peptide, or Protein · Biologically Active Substance
T68	Result_or_Value 1144 1147	<23
R42	Has_Result_or_Value Arg1:T37 Arg2:T68	
T69	Quantifier_or_Qualifier 1178 1191	significantes
#51	AnnotatorNotes T69	C1546944; Event Seriousness - Significant; Qualitative Concept
R44	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T69	
T70	Quantifier_or_Qualifier 1203 1210	clínica
#52	AnnotatorNotes T70	C0205210; Clinical; Qualitative Concept
R45	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T70	
T71	PROC 1283 1290	estudio
#53	AnnotatorNotes T71	C0008976; Clinical Trials; Research Activity
R46	Has_Quantifier_or_Qualifier Arg1:T59 Arg2:T60	
#54	AnnotatorNotes T60	C0205265; Initially; Temporal Concept
R47	After Arg1:T59 Arg2:T27	
R48	After Arg1:T59 Arg2:T28	
R51	Causes Arg1:T26 Arg2:T30	
R52	Causes Arg1:T26 Arg2:T31	
R53	Causes Arg1:T26 Arg2:T32	
R54	Causes Arg1:T33 Arg2:T30	
R55	Causes Arg1:T33 Arg2:T31	
R56	Causes Arg1:T33 Arg2:T32	
R57	Causes Arg1:T35 Arg2:T30	
R58	Causes Arg1:T35 Arg2:T31	
R59	Causes Arg1:T35 Arg2:T32	
R60	Causes Arg1:T36 Arg2:T30	
R61	Causes Arg1:T36 Arg2:T31	
R62	Causes Arg1:T36 Arg2:T32	
T72	Quantifier_or_Qualifier 1456 1463	severas
A9	Status T72 History_of
#55	AnnotatorNotes T72	C1547227; Severe - Severity of Illness Code; Intellectual Product
R63	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T72	
R69	Before Arg1:T10 Arg2:T66	
R38	Overlap Arg1:T58 Arg2:T21	
#56	AnnotatorNotes T16	C0040808; Treatment Protocols; Therapeutic or Preventive Procedure
#57	AnnotatorNotes T1	C1705187; Safety Study; Research Activity + C0201734; Pharmacokinetic study; Research Activity + C1709518; Pharmacodynamic Study; Research Activity
#58	AnnotatorNotes T7	C1705187; Safety Study; Research Activity + C0201734; Pharmacokinetic study; Research Activity + C1709518; Pharmacodynamic Study; Research Activity
A10	Experiencer T51 Patient
A11	Experiencer T42 Patient
A12	Experiencer T44 Patient
A13	Experiencer T52 Other
A14	Experiencer T53 Other
